News

The submission is based on results from Phase III trial, which evaluated the safety, tolerability and efficacy of Xtampza ER compared with placebo in opioid-experienced and opioid-naïve subjects

Injectafer was approved by the U.S. Food and Drug Administration (FDA) on July 25, 2013 for the treatment of IDA in adult patients who have intolerance to oral

On Monday, December 15, Judge Robert Sweet of the United States District Court for the Southern District of New York (New York City) issued a preliminary injunction requiring

As previously disclosed, PALOMA-1 achieved its primary endpoint with the combination of palbociclib and letrozole significantly prolonging progression-free survival (PFS) compared with letrozole alone in post-menopausal women with

Unlike traditional drug delivery platforms, Microchips Biotech’s implant is capable of responding to wireless signals, which can activate, deactivate or modify the frequency or dose of the drug,

The Vero cell platform is an advanced, cell-based technology for vaccines production. The agreement with Nanotherapeutics includes all assets related to the platform, including vaccines for H5N1, H1N1

The trial will be conducted with ADXS11-001 alone or in combination with MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736 The combination drug is indicated to treat advanced, recurrent

The deal will see the two parties establish a global strategic collaboration to jointly develop next generation immunotherapies to treat cancer and auto-immune diseases. NantWorks, through a subsidiary,

NEOD001 targets the circulating soluble amyloid and deposited insoluble amyloid that accumulates in both the AL and AA forms of amyloidosis. According to the company, this is the